The inverted pyramid of biomarker-driven trials

被引：0
|
作者：
Ignacio Garrido-Laguna
Manuel Hidalgo
Razelle Kurzrock
机构：
[1] The University of Texas MD Anderson Cancer Center,Departments of Investigational Cancer Therapeutics (A Phase I Program)
[2] Gastrointestinal Cancer Clinical Research Unit,undefined
[3] Spanish National Cancer Research Center,undefined
来源：
Nature Reviews Clinical Oncology | 2011年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Phase I trials have evolved from simple dose-finding studies to studies that provide therapeutic opportunities for patients where no standard therapy is available; however, various factors have hampered patient recruitment on phase I trials. The authors discuss how matching patients with specific genetic aberrations to specific therapies will improve drug attrition rates and improve patient outcomes.
引用
收藏
页码：562 / 566
页数：4
相关论文
共 50 条
  • [31] Novel therapies in urothelial carcinoma: a biomarker-driven approach
    Iyer, G.
    Rosenberg, J. E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (12) : 2302 - 2312
  • [32] Biomarker-driven and molecular targeted therapies for colorectal cancers
    Schirripa, Marta
    Cohen, Stacey A.
    Battaglin, Francesca
    Lenz, Heinz-Josef
    [J]. SEMINARS IN ONCOLOGY, 2018, 45 (03) : 124 - 132
  • [33] Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
    Robert Montal
    Carmen Andreu-Oller
    Laia Bassaganyas
    Roger Esteban-Fabró
    Sebastián Moran
    Carla Montironi
    Agrin Moeini
    Roser Pinyol
    Judit Peix
    Laia Cabellos
    Augusto Villanueva
    Daniela Sia
    Vincenzo Mazzaferro
    Manel Esteller
    Josep M. Llovet
    [J]. British Journal of Cancer, 2019, 121 : 340 - 343
  • [34] Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
    Montal, Robert
    Andreu-Oller, Carmen
    Bassaganyas, Laia
    Esteban-Fabro, Roger
    Moran, Sebastian
    Montironi, Carla
    Moeini, Agrin
    Pinyo, Roser
    Peix, Judit
    Cabellos, Laia
    Villanueva, Augusto
    Sia, Daniela
    Mazzaferro, Vincenzo
    Esteller, Manel
    Llovet, Josep M.
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 (04) : 340 - 343
  • [35] Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers
    Harris, William R.
    Wong, Kit Man
    Saha, Supriya
    El Dika, Imane
    Abou-Alfa, Ghassan K.
    [J]. SEMINARS IN ONCOLOGY, 2018, 45 (03) : 116 - 123
  • [36] Efficiency of Biomarker-Driven Clinical Trial Designs Reply
    Lee, Choong-kun
    Park, Sejung
    Nam, Chung Mo
    Chung, Hyun Cheol
    Rha, Sun Young
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12)
  • [37] Biomarker-driven immunotherapy for precision medicine in prostate cancer
    Ottini, Arianna
    Sepe, Pierangela
    Beninato, Teresa
    Claps, Melanie
    Guadalupi, Valentina
    Verzoni, Elena
    Giannatempo, Patrizia
    Baciarello, Giulia
    de Braud, Filippo
    Procopio, Giuseppe
    [J]. PERSONALIZED MEDICINE, 2022, 19 (01) : 51 - 66
  • [38] Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer
    Mishra, Prachi
    Laha, Dipranjan
    Grant, Robert
    Nilubol, Naris
    [J]. CANCERS, 2021, 13 (24)
  • [39] Novel Clinical Biomarker-Driven Endotyping for Chronic Rhinosinusitis
    Mahesh, Padukudru Anand
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (03): : 930 - 931
  • [40] Bayesian biomarker-driven outcome-adaptive randomization with an imperfect biomarker assay
    Garcia Barrado, Leandro
    Burzykowski, Tomasz
    [J]. CLINICAL TRIALS, 2021, 18 (02) : 137 - 146
12345